Abstract:We studied the long-term outcome of injection of triamcinolone acetonide into keloid scars in Asian patients. Between 1985 and 2003, we treated 109 keloid scars in 94 patients by injecting 1 to 10?mg of triamcinolone acetonide depending on the size of the lesion at four week intervals. There was little morbidity. Thirty-one patients gave up treatment within 10 injections because of pain and lack of immediate improvement. Improvement in subjective symptoms was seen in 52 of the remaining 63 patients (82%). In o… Show more
“…In our study, the overall remission rate (65%) was somewhat lower than in previous studies. Muneuchi et al also reported less favorable results than the previous studies; there was improvement in subjective symptoms in 82% of patients, but objectively the results were good or better in only 39% of the cases [30].…”
Section: Discussionmentioning
confidence: 39%
“…Muneuchi et al used 20-30 injections over 3-5 years, but reported only few local side effects. The concentration of TAC and the injection technique reported in their study did not differ from the technique generally used by professionals treating keloids [30].…”
Section: Discussionmentioning
confidence: 80%
“…Muneuchi et al, Sadheginia et al, and Davidsonet al did not report systemic complications or local adverse effects which needed further treatment [30,33,34]. We recorded 5 patients, who were operated on due to local side effects from TAC injections, but no systemic side effects in our follow-up.…”
Section: Discussionmentioning
confidence: 93%
“…According to several publications, intralesional TAC treatment is a standard first-line treatment modality in keloid scars [18,19,30,31]. It has also been the most common treatment option in our hospital.…”
Background: Intralesional triamcinolone acetonide (TAC) injections are often used as the first alternative for treating keloid scarring. The long-term outcome of this treatment is unclear. Also, undesirable local side effects have been recognized in clinical work and literature but they have been labelled as harmless and rare.
“…In our study, the overall remission rate (65%) was somewhat lower than in previous studies. Muneuchi et al also reported less favorable results than the previous studies; there was improvement in subjective symptoms in 82% of patients, but objectively the results were good or better in only 39% of the cases [30].…”
Section: Discussionmentioning
confidence: 39%
“…Muneuchi et al used 20-30 injections over 3-5 years, but reported only few local side effects. The concentration of TAC and the injection technique reported in their study did not differ from the technique generally used by professionals treating keloids [30].…”
Section: Discussionmentioning
confidence: 80%
“…Muneuchi et al, Sadheginia et al, and Davidsonet al did not report systemic complications or local adverse effects which needed further treatment [30,33,34]. We recorded 5 patients, who were operated on due to local side effects from TAC injections, but no systemic side effects in our follow-up.…”
Section: Discussionmentioning
confidence: 93%
“…According to several publications, intralesional TAC treatment is a standard first-line treatment modality in keloid scars [18,19,30,31]. It has also been the most common treatment option in our hospital.…”
Background: Intralesional triamcinolone acetonide (TAC) injections are often used as the first alternative for treating keloid scarring. The long-term outcome of this treatment is unclear. Also, undesirable local side effects have been recognized in clinical work and literature but they have been labelled as harmless and rare.
“…12,13 In the majority of patients, multiple intralesional injections are needed to obtain the desired clinical effect, i.e. flattening of the lesion and cessation of itching.…”
Intralesional triamcinolone acetonide injection in hypertrophic skin surrounding the percutaneous titanium implant of a bone-anchored hearing aid van Intralesional triamcinolone acetonide injection in hypertrophic skin surrounding the percutaneous titanium implant of a bone-anchored hearing aid
AbstractObjective:We present a patient with persistent hypertrophic skin surrounding the percutaneous implant of a bone-anchored hearing aid system, successfully treated with intralesional applied corticosteroids.Method:Case report and review of the world literature concerning bone-anchored hearing aid implantation and intralesional applied corticosteroids for the treatment of hypertrophic scars and keloids.Results:Eight weeks after revision surgery to reduce surplus skin and subcutaneous scar tissue overgrowing the abutment, skin and subcutaneous scar tissue overgrowth reoccurred. As an alternative to yet another surgical procedure, the hypertrophic skin was treated with intralesional injections of triamcinolone acetonide. Three weeks after the treatment, a satisfying result was seen, and no subsequent relapse was observed.Conclusion:To our knowledge, this is the first, photographically well documented case report of a patient with persistent hypertrophic skin surrounding a percutaneous bone-anchored hearing aid implant, successfully treated with intralesional applied corticosteroids.
Clinical RecordIntralesional triamcinolone acetonide injection in hypertrophic skin surrounding the percutaneous titanium implant of a bone-anchored hearing aid J B VAN RIJSWIJK, E A M MYLANUS*
AbstractObjective: We present a patient with persistent hypertrophic skin surrounding the percutaneous implant of a bone-anchored hearing aid system, successfully treated with intralesional applied corticosteroids. Method: Case report and review of the world literature concerning bone-anchored hearing aid implantation and intralesional applied corticosteroids for the treatment of hypertrophic scars and keloids.Results: Eight weeks after revision surgery to reduce surplus skin and subcutaneous scar tissue overgrowing the abutment, skin and subcutaneous scar tissue overgrowth reoccurred. As an alternative to yet another surgical procedure, the hypertrophic skin was treated with intralesional injections of triamcinolone acetonide. Three weeks after the treatment, a satisfying result was seen, and no subsequent relapse was observed.Conclusion: To our knowledge, this is the first, photographically well documented case report of a patient with persistent hypertrophic skin surrounding a percutaneous bone-anchored hearing aid implant, successfully treated with intralesional applied corticosteroids.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.